Welcome to our dedicated page for Fate Therapeutics news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics stock.
Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ: FATE) will present preclinical data for its next‑generation off‑the‑shelf CAR T candidate FT839 at the AACR Annual Meeting, April 17–22, 2026 in San Diego.
FT839 is described as a 13‑point edited, dual‑CAR product targeting CD19 and CD38, using Sword and Shield™ technology to evade host immune responses and potentially remove the need for conditioning chemotherapy. Poster: April 21, 2026, 9:00 a.m.–Noon PDT.
Fate Therapeutics (NASDAQ: FATE) said management will participate in five investor conferences in Q2 2026 with scheduled dates and locations listed below.
- April 14 — Needham Virtual Healthcare Conference (virtual)
- May 13 — Bank of America Healthcare Conference, Las Vegas
- May 19 — H.C. Wainwright BioConnect, New York
- June 4 — Jefferies Global Healthcare, New York
- June 10 — Goldman Sachs Global Healthcare, Miami Beach
The company said presentations or fireside chats may occur and live webcasts will be available under Events & Presentations on the company website, with archived replays accessible for 30 days.
Fate Therapeutics (NASDAQ: FATE) granted 7,260 restricted stock units (RSUs) on April 1, 2026 to one newly hired non-executive employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved the award under the companys Amended and Restated Inducement Equity Plan.
The RSUs vest over four years with 25% vesting on each anniversary, subject to continuous employment through each vesting date.
Fate Therapeutics (NASDAQ: FATE) granted restricted stock units representing 50,700 shares to three newly hired non-executive employees on March 2, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The awards vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.
Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.
Fate Therapeutics (NASDAQ: FATE) reported Q4 and full-year 2025 results and clinical progress on Feb 26, 2026. The company ended 2025 with $205.1 million in cash, projects runway through year-end 2027, and recorded Q4 revenue of $1.4 million. FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed a 3-month improvement in a systemic sclerosis patient. FT836 showed a >50% CEA reduction in a CRC patient without conditioning chemotherapy. Operating expenses declined ~30% in 2025 versus 2024.
Fate Therapeutics (NASDAQ: FATE) granted inducement awards on February 1, 2026 to a newly-hired non-executive employee under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The package includes 120,000 non-qualified stock options at an exercise price of $1.19 per share and 90,000 restricted stock units (RSUs). Options vest over four years (25% at one year, remainder monthly over 36 months); RSUs vest 25% each anniversary over four years, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) announced inducement equity awards granted on January 1, 2026 to newly hired non-executive employees under its Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The company granted a non-qualified stock option for 48,000 shares at an exercise price of $0.98 (NASDAQ close on December 31, 2025) to one new hire and 79,400 restricted stock units (RSUs) to four new hires (one individual received both the option and RSUs). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary, subject to continued employment.
Fate Therapeutics (NASDAQ: FATE) presented updated Phase 1 data for off-the-shelf CAR T candidate FT819 and preclinical advances for FT836 and FT839 at ASH 2025. 13 patients enrolled (12 SLE, 1 SSc); 10 SLE patients had ≥1 month follow-up. FT819 showed progressive mean SLEDAI-2K score reductions (DL1: 50% at 3 months, 70% at 6 months; DL2: 65% at 3 months, 78% at 6 months [n=1 at 6 months]), durable B‑cell depletion, meaningful FACIT‑fatigue improvements, no Grade >2 CRS/ICANS/GVHD, and on‑demand dosing from inventory. Company plans to discuss a registrational trial for FT819 in 2026 under RMAT. Preclinical FT836/FT839 data show expanded antigen targeting and conditioning‑free approaches for hematologic and autoimmune indications.
Fate Therapeutics (NASDAQ: FATE) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.
A live webcast of each presentation, if recorded, will be accessible under “Events & Presentations” in the Investors section at www.fatetherapeutics.com, and archived webcasts will be posted on the company website shortly after the event.